Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised double-blind placebo-controlled Phase 2 trial of AZD8233 in hyperlipidaemia
2020-005845-18Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperlipidemia comparing AZD8233 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started May 2021; status: completed.
02
Drugs
AZD8233
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on 2020-005845-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005845-18.